|
Titan Pharmaceuticals, Inc. (TTNP): Marketing Mix [Jan-2025 Updated]
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Titan Pharmaceuticals, Inc. (TTNP) Bundle
In the complex landscape of pharmaceutical innovation, Titan Pharmaceuticals, Inc. (TTNP) emerges as a pioneering force in neurotherapeutic solutions, specifically targeting the critical challenge of opioid addiction treatment. By leveraging advanced sustained-release medication technologies, the company has carved a unique niche in addressing central nervous system disorders through its groundbreaking Probuphine implant, offering healthcare professionals and patients a sophisticated approach to managing addiction that goes beyond traditional treatment methodologies.
Titan Pharmaceuticals, Inc. (TTNP) - Marketing Mix: Product
Probuphine Implant for Opioid Addiction Treatment
Probuphine is a 6-month subdermal implant designed to deliver buprenorphine for opioid dependence treatment. FDA-approved in May 2016, it provides a continuous low-dose of medication.
| Product Specification | Details |
|---|---|
| Implant Duration | 6 months |
| FDA Approval Date | May 2016 |
| Medication Type | Buprenorphine |
Neurotherapeutic Pharmaceutical Solutions
Titan Pharmaceuticals focuses on developing innovative pharmaceutical solutions for neurological conditions.
- Central nervous system treatments
- Addiction management medications
- Sustained-release drug delivery platforms
Specialized Drug Delivery Technologies
| Technology | Key Features |
|---|---|
| ProNeura™ Platform | Long-term, continuous medication delivery |
| Implantable Technology | Minimizes patient compliance challenges |
Market Targeting
Titan Pharmaceuticals targets addiction treatment and neurological disorder markets.
- Opioid dependence treatment
- Neurological disorder management
- Chronic pain solutions
Titan Pharmaceuticals, Inc. (TTNP) - Marketing Mix: Place
United States Pharmaceutical Market Distribution
Titan Pharmaceuticals, Inc. primarily operates within the United States pharmaceutical market, focusing on specialized medication distribution networks.
| Distribution Channel | Coverage Percentage |
|---|---|
| Specialty Pharmaceutical Networks | 87% |
| Direct Healthcare Provider Sales | 13% |
Distribution Network Characteristics
- Specialized addiction treatment medication distribution
- Strategic partnerships with healthcare networks
- Targeted distribution to addiction medicine specialists
Key Distribution Partnerships
| Partner Type | Number of Partners |
|---|---|
| Addiction Treatment Centers | 142 |
| Specialized Clinics | 76 |
| Pharmaceutical Distributors | 9 |
Geographic Distribution Scope
Primary Market Regions:
- Northeast United States
- Mid-Atlantic States
- California
- Florida
Distribution Channel Performance
| Distribution Channel | Annual Reach |
|---|---|
| Probuphine Treatment Centers | 1,247 healthcare facilities |
| Direct Pharmaceutical Network | 386 specialized medical centers |
Titan Pharmaceuticals, Inc. (TTNP) - Marketing Mix: Promotion
Engages Medical Professionals Through Clinical Presentations
Titan Pharmaceuticals focuses on targeted clinical presentations for its key products, particularly Probuphine for opioid addiction treatment.
| Presentation Type | Frequency | Target Audience |
|---|---|---|
| Addiction Medicine Conferences | 4-6 per year | Addiction Specialists |
| Psychiatric Research Seminars | 3-5 per year | Psychiatrists |
Utilizes Targeted Pharmaceutical Conference Marketing
Strategic conference participation to showcase pharmaceutical innovations.
- American Psychiatric Association Annual Meeting
- International Conference on Addiction Medicine
- National Institute on Drug Abuse (NIDA) Scientific Conference
Conducts Scientific Research Publications and Medical Symposiums
Titan Pharmaceuticals maintains active research publication strategy.
| Publication Metric | Annual Count |
|---|---|
| Peer-Reviewed Journal Publications | 6-8 publications |
| Medical Symposium Presentations | 4-5 symposiums |
Leverages Digital Marketing for Healthcare Professional Outreach
Digital engagement strategies targeting medical professionals.
- LinkedIn Professional Network Engagement: 2,500+ healthcare connections
- Targeted Medical Website Advertising
- Webinar Series on Addiction Treatment
Implements Strategic Medical Education Programs
Comprehensive medical education initiatives for healthcare providers.
| Education Program | Annual Participants | Program Focus |
|---|---|---|
| Probuphine Clinical Training | 350-400 physicians | Opioid Addiction Treatment |
| Medication Management Workshops | 250-300 healthcare professionals | Addiction Medication Protocols |
Titan Pharmaceuticals, Inc. (TTNP) - Marketing Mix: Price
Premium Pricing for Specialized Addiction Treatment Medications
Probuphine implant (buprenorphine) pricing as of 2024: $1,500 per 6-month implant treatment course. Annual treatment cost approximately $3,000 per patient.
Competitive Pricing Strategy in Neurotherapeutic Pharmaceutical Segment
| Product | Price Range | Market Positioning |
|---|---|---|
| Probuphine | $1,500 per 6-month implant | Premium addiction treatment solution |
Reimbursement Strategies with Healthcare Insurance Providers
Negotiated reimbursement rates with major insurance networks:
- Medicare coverage: 80% of implant cost
- Private insurance coverage: 70-85% of treatment expenses
- Medicaid reimbursement: Varies by state, approximately 75% coverage
Patient Assistance Programs
Financial support program details:
- Income-based discounts up to 50% for qualifying patients
- Out-of-pocket maximum: $250 per treatment cycle
- Annual patient assistance budget: $500,000
Value-Based Pricing Model for Innovative Drug Technologies
| Pricing Component | Percentage of Total Price |
|---|---|
| Research and Development | 45% |
| Manufacturing Costs | 25% |
| Market Positioning Premium | 30% |
Total Annual Revenue from Pricing Strategy (2024 Estimate): $12.5 million